Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Amgen developing intracellular therapies with Elasmogen, Feldan

May 9, 2017 1:24 PM UTC

Elasmogen Ltd. (Aberdeen, U.K.) and Feldan Therapeutics Inc. (Quebec, Quebec) partnered with Amgen Inc. (NASDAQ:AMGN) to develop candidates targeting two undisclosed intracellular targets.

The companies will use Feldan's Shuttle platform in combination with Elasmogen's soloMER technology. Feldan's Shuttle uses a peptide-based delivery system to introduce proteins into cells. The companies said soloMER biologics are 9% of the size of an antibody, and are derived from variable new-antigen receptors (VNARS)...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article